[go: up one dir, main page]

WO2007014992A3 - Anticorps diriges contre le recepteur du ldl - Google Patents

Anticorps diriges contre le recepteur du ldl Download PDF

Info

Publication number
WO2007014992A3
WO2007014992A3 PCT/FR2006/001807 FR2006001807W WO2007014992A3 WO 2007014992 A3 WO2007014992 A3 WO 2007014992A3 FR 2006001807 W FR2006001807 W FR 2006001807W WO 2007014992 A3 WO2007014992 A3 WO 2007014992A3
Authority
WO
WIPO (PCT)
Prior art keywords
directed against
ldl receptor
antibodies directed
cirrhosis
ldl
Prior art date
Application number
PCT/FR2006/001807
Other languages
English (en)
Other versions
WO2007014992A2 (fr
Inventor
Christian Behrens
Christine Gaucher
Jean-Francois Prost
Jamila Najib
Original Assignee
Lab Francais Du Fractionnement
Christian Behrens
Christine Gaucher
Jean-Francois Prost
Jamila Najib
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement, Christian Behrens, Christine Gaucher, Jean-Francois Prost, Jamila Najib filed Critical Lab Francais Du Fractionnement
Priority to AU2006274752A priority Critical patent/AU2006274752A1/en
Priority to EP06794207A priority patent/EP1937722A2/fr
Priority to CA002618050A priority patent/CA2618050A1/fr
Priority to JP2008524539A priority patent/JP2009502189A/ja
Publication of WO2007014992A2 publication Critical patent/WO2007014992A2/fr
Publication of WO2007014992A3 publication Critical patent/WO2007014992A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un anticorps monoclonal dirigé contre le récepteur humain des LDL (Low Density Lipoprotein), se liant au peptide correspondant aux acides aminés 280-307 (SEQ ID NO : 1) de la séquence peptidique du récepteur des LDL, son utilisation comme médicament, une composition pharmaceutique contenant cet anticorps, ainsi que son utilisation dans les analyses immunohistochimiques de tissus cancéreux, sains ou cirrhoses, en western blot, en ELISA ou en test de quantification in vivo.
PCT/FR2006/001807 2005-08-03 2006-07-25 Anticorps diriges contre le recepteur du ldl WO2007014992A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2006274752A AU2006274752A1 (en) 2005-08-03 2006-07-25 Antibodies directed against an LDL receptor
EP06794207A EP1937722A2 (fr) 2005-08-03 2006-07-25 Anticorps dirigés contre le récepteur du ldl
CA002618050A CA2618050A1 (fr) 2005-08-03 2006-07-25 Anticorps diriges contre le recepteur du ldl
JP2008524539A JP2009502189A (ja) 2005-08-03 2006-07-25 Ｌｄｌ受容体に対する抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508281A FR2889532B1 (fr) 2005-08-03 2005-08-03 Anticorps diriges contre le recepteur du ldl
FR0508281 2005-08-03

Publications (2)

Publication Number Publication Date
WO2007014992A2 WO2007014992A2 (fr) 2007-02-08
WO2007014992A3 true WO2007014992A3 (fr) 2007-04-19

Family

ID=35883519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/001807 WO2007014992A2 (fr) 2005-08-03 2006-07-25 Anticorps diriges contre le recepteur du ldl

Country Status (6)

Country Link
EP (1) EP1937722A2 (fr)
JP (1) JP2009502189A (fr)
AU (1) AU2006274752A1 (fr)
CA (1) CA2618050A1 (fr)
FR (1) FR2889532B1 (fr)
WO (1) WO2007014992A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
KR102063341B1 (ko) 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
CA3128035A1 (fr) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Polytherapies pour l'administration dans l'ensemble de la barriere hemato-encephalique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000279174A (ja) * 1999-03-30 2000-10-10 Bml Inc ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法
WO2001068710A1 (fr) * 2000-03-13 2001-09-20 Applied Research Systems Ars Holding N.V. Anticorps monoclonaux anti-recepteur de ldl humain, leur preparation et utilisation
JP2004529080A (ja) * 2000-10-25 2004-09-24 アグネッロ，ヴィンセント Ｈｃｖ、他のフラビウイルス科ウイルス、および血液中で低密度リポタンパク質または超低密度リポタンパク質と複合体を形成するその他のあらゆるウイルスによる感染を細胞中へのウイルス侵入を抑制することによって防止する方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000279174A (ja) * 1999-03-30 2000-10-10 Bml Inc ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法
WO2001068710A1 (fr) * 2000-03-13 2001-09-20 Applied Research Systems Ars Holding N.V. Anticorps monoclonaux anti-recepteur de ldl humain, leur preparation et utilisation
JP2004529080A (ja) * 2000-10-25 2004-09-24 アグネッロ，ヴィンセント Ｈｃｖ、他のフラビウイルス科ウイルス、および血液中で低密度リポタンパク質または超低密度リポタンパク質と複合体を形成するその他のあらゆるウイルスによる感染を細胞中へのウイルス侵入を抑制することによって防止する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 13 5 February 2001 (2001-02-05) *

Also Published As

Publication number Publication date
AU2006274752A1 (en) 2007-02-08
JP2009502189A (ja) 2009-01-29
EP1937722A2 (fr) 2008-07-02
FR2889532A1 (fr) 2007-02-09
FR2889532B1 (fr) 2007-10-12
WO2007014992A2 (fr) 2007-02-08
CA2618050A1 (fr) 2007-02-08

Similar Documents

Publication Publication Date Title
EP2343318A3 (fr) Anticorps se liant à un fragment C-terminal de l'apolipoprotein E
JP2004532817A5 (fr)
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
EP2399936A3 (fr) Anticorps anti-CD154
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
WO2006116442A3 (fr) Anticorps monoclonaux et leurs methodes d'utilisation dans la detection d'une maladie cervicale
WO2006073941A3 (fr) Polypeptides de liaison a la br3 et leurs utilisations
EP2716658A3 (fr) Anticorps et procédés de fabrication et d'utilisation de ceux-ci
EP2368913A3 (fr) Anticorps glyco-modifiés
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
MX2008009886A (es) Anticuerpos que enlazan par-2.
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
WO2005018424A3 (fr) Anticorps specifiques de la proteine amyloide fibrillaire et procedure permettant de detecter des depots de proteines amyloides fibrillaires
TW200736277A (en) RANKL antibody-PTH/PTHrP chimeric molecules
EP2645106A3 (fr) Procédés et produits pour évaluer une réponse immunitaire à un agent thérapeutique
WO2004081028A3 (fr) Fragments de peptides d'allergene et leur utilisation
WO2000005249A3 (fr) Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
WO2005117952A3 (fr) Methodes de traitement dans lesquelles des proteines de liaison de l'albumine sont utilisees
WO2007039256A3 (fr) Domaines de liaison de proteines de la famille proteinique des molecules de guidage repulsif (rgm), fragments fonctionnels de ces domaines et leur utilisation
WO2007111661A3 (fr) anticorps humains specifiques a des matieres et des procedes a base de gastrine
WO2002036625A3 (fr) Polypeptides de prokineticine, et methodes et compositions associees
ATE460430T1 (de) Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
WO2007014992A3 (fr) Anticorps diriges contre le recepteur du ldl
EP1433792A8 (fr) Protéines réceptrices humaines, réactifs et méthodes associés
WO2005087811A3 (fr) Recepteurs des oestrogenes et procedes d'utilisation associes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008524539

Country of ref document: JP

Ref document number: 2618050

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006274752

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006794207

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006274752

Country of ref document: AU

Date of ref document: 20060725

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006274752

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006794207

Country of ref document: EP